MX2023007244A - Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8. - Google Patents
Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8.Info
- Publication number
- MX2023007244A MX2023007244A MX2023007244A MX2023007244A MX2023007244A MX 2023007244 A MX2023007244 A MX 2023007244A MX 2023007244 A MX2023007244 A MX 2023007244A MX 2023007244 A MX2023007244 A MX 2023007244A MX 2023007244 A MX2023007244 A MX 2023007244A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibiting
- treating
- voltage
- sodium channels
- gated sodium
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 108010056565 NAV1.8 Voltage-Gated Sodium Channel Proteins 0.000 title abstract 2
- 102000004194 NAV1.8 Voltage-Gated Sodium Channel Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen compuestos de la fórmula (I), en donde cada uno de los grupos variables es como se define en la memoria descriptiva. También se describen composiciones farmacéuticas que contienen un compuesto de la fórmula (I), y usos de los compuestos y composiciones farmacéuticas para inhibir los canales de sodio dependientes de voltaje de Nav1.8 y tratar enfermedades, trastornos y afecciones mediados por Nav1.8, tales como dolor y enfermedades, trastornos y afecciones asociados al dolor y enfermedades, trastornos y afecciones cardiovasculares. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063127341P | 2020-12-18 | 2020-12-18 | |
PCT/EP2021/086101 WO2022129283A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023007244A true MX2023007244A (es) | 2023-06-29 |
Family
ID=79025144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023007244A MX2023007244A (es) | 2020-12-18 | 2021-12-16 | Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4262978A1 (es) |
JP (1) | JP2024502231A (es) |
KR (1) | KR20230121827A (es) |
CN (1) | CN116710463A (es) |
AU (1) | AU2021403606A1 (es) |
CA (1) | CA3202328A1 (es) |
CL (1) | CL2023001750A1 (es) |
CO (1) | CO2023008049A2 (es) |
IL (1) | IL303795A (es) |
MX (1) | MX2023007244A (es) |
WO (1) | WO2022129283A1 (es) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ760006A (en) * | 2013-12-13 | 2022-07-29 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
-
2021
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko unknown
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja active Pending
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en active Application Filing
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en active Pending
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
- 2021-12-16 AU AU2021403606A patent/AU2021403606A1/en active Pending
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230121827A (ko) | 2023-08-21 |
CN116710463A (zh) | 2023-09-05 |
CA3202328A1 (en) | 2022-06-23 |
AU2021403606A1 (en) | 2023-06-22 |
CL2023001750A1 (es) | 2024-01-19 |
CO2023008049A2 (es) | 2023-06-30 |
JP2024502231A (ja) | 2024-01-18 |
EP4262978A1 (en) | 2023-10-25 |
IL303795A (en) | 2023-08-01 |
WO2022129283A1 (en) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
CY1109906T1 (el) | Παραγωγα c3-kyano εποθιλονης | |
MA27697A1 (fr) | Derive de phenethanolamine utilise dans le traitement des maladies respiratoires | |
MXPA05006573A (es) | Metodos para el tratamiento de dolor y dano traumatico usando benzamidas y composiciones que las contienen. | |
MA27946A1 (fr) | Omega-carboxyaryldiphenyluree fluoro-substituee pour le traitement et la prevention de maladies et d'etats pathologiques. | |
IL163629A0 (en) | Glutaminyl derivatives and pharmaceutical compositions containing the same | |
MA26727A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
GEP20043265B (en) | Acetylenic alpha -Amino Acid-Based Sulfonamide Hydroxamic Acid TACE Inhibitors, Methods for Their Production, Pharmaceutical Compositions Containing the Same and Their Use for Inhibiting Pathological Conditions Mediated by TNF- Alpha Ferment (TACE) With Mammalians | |
MX2022014942A (es) | Nuevos compuestos. | |
TNSN05238A1 (fr) | Derives du benzenesulfonamide, leur procede de preparation et leur utilisation pour le traitement de la douleur | |
GB0313612D0 (en) | Organic compounds | |
MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
MX2022013637A (es) | Nuevos compuestos de triazinoindol. | |
MX2022013323A (es) | Compuestos triciclicos como inhibidores de nlrp3. | |
CR20210630A (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
MX2023001997A (es) | Compuestos biciclicos, composiciones y usos de los mismos. | |
MX2023003264A (es) | Inhibidores de cdk y su uso como productos fármaceuticos. | |
NZ512526A (en) | 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin. | |
MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. | |
MX2023007244A (es) | Compuestos quimicos utiles para inhibir los canales de sodio activados por voltaje de nav1.8 y tratar las enfermedades mediadas por nav1.8. | |
MX2023003459A (es) | Nuevos compuestos. | |
CA3200722A1 (en) | Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications | |
MX2023006881A (es) | Antagonistas del receptor de adenosina a2a. | |
BR0308837A (pt) | Composto, composição, método e medicamento para o tratamento de infecções bacterianas, psorìase ou artrite em mamìferos, método e medicamento para o tratamento de toxicidade devido a quimioterapia em um paciente, composição farmacêutica, processo para a preparação de um composto e processo para a conversão dos compostos da fórmula (i) em compostos adicionais da fórmula (i) |